Skip to main content
Clinical Trials/NCT04327752
NCT04327752
Completed
Not Applicable

Cutaneous Adverse Effects Occurring in Children Under Biological Therapy Given for Chronic Inflammatory Diseases

Centre Hospitalier Universitaire, Amiens1 site in 1 country20 target enrollmentMarch 12, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Biotherapy
Sponsor
Centre Hospitalier Universitaire, Amiens
Enrollment
20
Locations
1
Primary Endpoint
Variation of the incidence of cutaneous adverse events under biological therapy
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

Biological treatments (BT) are commonly prescribed to treat chronic inflammatory diseases in children. Paradoxical reactions during treatment with a biological agent can be defined as the appearance or exacerbation of a pathological condition that usually responds to this class of drug while treating a patient for another condition. Limited data are available in children treated by BT on cutaneous paradoxical reactions, or any other cutaneous adverse events occurring during treatment. On the contrary, dermatologists tend to see and manage increasing numbers of cutaneous adverse events, including paradoxical reactions. The aim of this project is to describe the incidence of cutaneous adverse events, including cutaneous paradoxical reactions, occurring in the pediatric population, during a treatment by BT given for a chronic inflammatory disease.

Registry
clinicaltrials.gov
Start Date
March 12, 2020
End Date
October 1, 2020
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Children under 18 years old
  • Children treated by biotherapy among : Adalimumab, Golimumab, Infliximab, Ustekinumab, Etanercept, Tocilizumab, Canakinumab, Anakinra, Abatacept.
  • Children treated for a chronic inflammatory disease (rheumatologic, gastro-enterologic, dermatologic and ophthalmologic)
  • Children treated in the CHU of Amiens
  • Parental consent signed

Exclusion Criteria

  • Age \> 18 ans

Outcomes

Primary Outcomes

Variation of the incidence of cutaneous adverse events under biological therapy

Time Frame: up to 8 months

Determine the variation of the incidence of any skin manifestation under biological therapy, including Paradoxical Reaction (psoriasis, eczema, hidradenitis suppurativa ...), non-paradoxical inflammatory reaction, infection, neoplasia, hair and nail manifestation, xerosis.

Study Sites (1)

Loading locations...

Similar Trials